These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 5044500)

  • 1. Studies for safety of adjuvant 65.
    Hilleman MR; Woodhour AF; Friedman A; Phelps AH
    Ann Allergy; 1972 Aug; 30(8):477-83. PubMed ID: 5044500
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience in the United Kingdom with oil adjuvant influenza vaccines.
    Perkins FT
    Ann Allergy; 1972 May; 30(5):288-91. PubMed ID: 5063341
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical application of adjuvant 65.
    Hilleman MR; Woodhour A; Friedman A; Weibel RE; Stokes J
    Ann Allergy; 1972 Mar; 30(3):152-8. PubMed ID: 4622116
    [No Abstract]   [Full Text] [Related]  

  • 4. Mineral oil adjuvants: biological and chemical studies.
    Murray R; Cohen P; Hardegree MC
    Ann Allergy; 1972 Mar; 30(3):146-51. PubMed ID: 4622115
    [No Abstract]   [Full Text] [Related]  

  • 5. [Protective effect of the domestic oil adjuvant vaccine against influenza (1 year after vaccination)].
    Bervar M; Papo I; Piscević S; Duknić M
    Vojnosanit Pregl; 1971 Oct; 28(10):505-11. PubMed ID: 5134859
    [No Abstract]   [Full Text] [Related]  

  • 6. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness.
    Süli J; Benísek Z; Eliás D; Svrcek S; Ondrejková A; Ondrejka R; Bajová V
    Vaccine; 2004 Sep; 22(25-26):3464-9. PubMed ID: 15308373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice.
    Wang S; Ke CW; Zou LR; Jing Z; Xie GX; Li X
    Intervirology; 2009; 52(5):252-7. PubMed ID: 19622895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
    Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
    Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of new parenteral adjuvants.
    WOODHOUR AF; JENSEN KE; WARREN J
    J Immunol; 1961 Jun; 86():681-9. PubMed ID: 13786540
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant formulations for experimental vaccines.
    Stewart-Tull DE
    Methods Mol Med; 2003; 87():175-94. PubMed ID: 12958456
    [No Abstract]   [Full Text] [Related]  

  • 14. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.
    Fox CB; Anderson RC; Dutill TS; Goto Y; Reed SG; Vedvick TS
    Colloids Surf B Biointerfaces; 2008 Aug; 65(1):98-105. PubMed ID: 18440205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR; Crane RT
    Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical appraisal of emulsified oil adjuvants applied to viral vaccines.
    Hilleman MR
    Prog Med Virol; 1966; 8():131-82. PubMed ID: 5333821
    [No Abstract]   [Full Text] [Related]  

  • 18. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New metabolizable immunologic adjuvant for human use. 4. Development of highly purified influenza virus vaccine in adjuvant 65.
    Woodhour AF; Metzgar DP; Lampson GP; Machlowitz RA; Tytell AA; Hilleman MR
    Proc Soc Exp Biol Med; 1966 Dec; 123(3):778-82. PubMed ID: 5959017
    [No Abstract]   [Full Text] [Related]  

  • 20. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    O'Hagan DT; Wack A; Podda A
    Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.